Neuromyelitis OpticaSymptoms, Doctors, Treatments, Advances & More
Learn About Neuromyelitis Optica
Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.
No genes associated with neuromyelitis optica have been identified. However, a small percentage of people with this condition have a family member who is also affected, which indicates that there may be one or more genetic changes that increase susceptibility. It is thought that the inheritance of this condition is complex and that many environmental and genetic factors are involved in the development of the condition.
Neuromyelitis optica affects approximately 1 to 2 per 100,000 people worldwide. Women are affected by this condition more frequently than men.
Neuromyelitis optica is usually not inherited. Rarely, this condition is passed through generations in families, but the inheritance pattern is unknown.
Johns Hopkins Outpatient Center
Elias Sotirchos, M.D., specializes in the diagnosis, management and treatment of neuroimmunological disorders that involve the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). His research focuses on developing and validating novel imaging and blood-based biomarkers of these conditions, and clinical trials of experimental therapeutic agents. Dr. Sotirchos earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his internship and neurology residency training at The Johns Hopkins Hospital. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National MS Society Sylvia Lawry Fellow. Dr. Sotirchos is rated as an Elite provider by MediFind in the treatment of Neuromyelitis Optica. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Optic Neuritis, Multiple Sclerosis (MS), Neuromyelitis Optica, and Transverse Myelitis. Dr. Sotirchos is board certified in American Board Of Psychiatry And Neurology.
Vanderbilt Medical Group- Teleneurology
Francesca Bagnato is a Neurologist practicing medicine in Nashville, Tennessee. Dr. Bagnato is rated as a Distinguished provider by MediFind in the treatment of Neuromyelitis Optica. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Multiple Sclerosis (MS), Neuromyelitis Optica, Optic Neuritis, and Relapsing Multiple Sclerosis (RMS). Dr. Bagnato is board certified in .
Multiple Sclerosis Center
Dr. Pavle Repovic is a Neurologist at the Swedish Neuroscience Institute that specializes in the treatment of Multiple Sclerosis. He offers his patients the guidance and support to effectively manage their condition and lead a fuller life. In his spare time he is interested in foreign languages, cultures and cuisine; tango and nature. Dr. Repovic was also selected by Seattle Magazine as a Top Doctor in Neurology. Dr. Repovic is rated as a Distinguished provider by MediFind in the treatment of Neuromyelitis Optica. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), Neuromyelitis Optica, and Optic Neuritis. Dr. Repovic is board certified in American Board Of Psychiatry And Neurology.
Summary: This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to 3+3 design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of recurrent/refractory antibody-mediated neurological autoimmune diseases.
Summary: This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simp...
Published Date: March 01, 2015
Published By: National Institutes of Health